Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
InMed Pharmaceuticals (INM)
NASDAQ:INM
RESEARCH TOOLSreports
InMed Pharmaceuticals (INM) Stock Price & Analysis
257 Followers
INM Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.21 - $2.08
Previous Close$0.25
Volume203.70K
Average Volume (3M)800.39K
Market Cap
$2.26M
Enterprise Value-$4.31M
Total Cash (Recent Filing)$7.64M
Total Debt (Recent Filing)$1.07M
Price to Earnings (P/E)―
Beta1.79
Next Earnings
Sep 20, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.23
Shares Outstanding8,357,956
10 Day Avg. Volume1,425,960
30 Day Avg. Volume800,388
Standard Deviation0.21
R-Squared0.02
Alpha-0.09
Financial Highlights & Ratios
Price to Book (P/B)0.19
Price to Sales (P/S)0.51
Price to Cash Flow (P/CF)-0.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-0.77
Enterprise Value/Gross Profit-3.07
Enterprise Value/Ebitda0.79
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
InMed Pharmaceuticals News
PremiumCompany Announcements
InMed Pharmaceuticals to Showcase at Growth Conference
PremiumCompany Announcements
InMed Pharmaceuticals Releases Q3 Financial UpdatePremiumCompany Announcements
InMed Pharmaceuticals Excels in Q3 with Promising Trials
PremiumCompany Announcements
InMed Pharmaceuticals Strengthens Alzheimer’s Program with New Expert
PremiumCompany Announcements
InMed Pharmaceuticals Welcomes Alzheimer’s Expert
PremiumCompany Announcements
InMed Pharmaceuticals Preclinical Success with INM-089
PremiumCompany Announcements
InMed’s INM-089 Shows Promise for AMD Treatment
PremiumCompany Announcements
InMed Pharmaceuticals Excites with Alzheimer’s BreakthroughRisk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
INM FAQ
What was InMed Pharmaceuticals’s price range in the past 12 months?
InMed Pharmaceuticals lowest stock price was $0.21 and its highest was $2.08 in the past 12 months.
What is InMed Pharmaceuticals’s market cap?
Currently, no data Available
When is InMed Pharmaceuticals’s upcoming earnings report date?
InMed Pharmaceuticals’s upcoming earnings report date is Sep 20, 2024 which is in 76 days.
How were InMed Pharmaceuticals’s earnings last quarter?
InMed Pharmaceuticals released its earnings results on May 14, 2024. The company reported -$0.18 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.18.
Is InMed Pharmaceuticals overvalued?
According to Wall Street analysts InMed Pharmaceuticals’s price is currently Overvalued.
Does InMed Pharmaceuticals pay dividends?
InMed Pharmaceuticals does not currently pay dividends.
What is InMed Pharmaceuticals’s EPS estimate?
InMed Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does InMed Pharmaceuticals have?
InMed Pharmaceuticals has 8,918,956 shares outstanding.
What happened to InMed Pharmaceuticals’s price movement after its last earnings report?
InMed Pharmaceuticals reported an EPS of -$0.18 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.571%.
Which hedge fund is a major shareholder of InMed Pharmaceuticals?
Currently, no hedge funds are holding shares in INM
---
InMed Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-72.50%
12-Months-Change
Fundamentals
Return on Equity
-51.73%
Trailing 12-Months
Asset Growth
-9.31%
Trailing 12-Months
Company Description
InMed Pharmaceuticals
InMed Pharmaceuticals, Inc. engages in the research and development of cannabinoid-based therapies and biosynthesis system for the manufacturing of pharmaceutical-grade cannabinoids. It offers pipeline of medications that target diseases with unmet medical needs, such as epidermolysis bullosa, glaucoma, and orofacial pain. The company was founded by Christopher Bogart, Sazzad Hossain, Hyder A. Khoja, and Craig D. Schneider on May 19, 1981 and is headquartered in Vancouver, Canada.
---
Technical Analysis
---